Danaher (NYSE:DHR) Price Target Raised to $278.00

Danaher (NYSE:DHR) had its price target upped by Evercore ISI from $275.00 to $278.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the conglomerate’s stock.

A number of other analysts also recently issued reports on the stock. Barclays increased their target price on shares of Danaher from $270.00 to $285.00 and gave the stock an equal weight rating in a research report on Wednesday, July 24th. The Goldman Sachs Group increased their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a neutral rating in a research report on Wednesday, July 24th. Wells Fargo & Company began coverage on Danaher in a report on Tuesday, August 27th. They issued an equal weight rating and a $280.00 price target for the company. Jefferies Financial Group began coverage on Danaher in a report on Monday, June 3rd. They issued a buy rating and a $295.00 price target for the company. Finally, Stephens began coverage on Danaher in a report on Tuesday. They issued an overweight rating and a $315.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has a consensus rating of Moderate Buy and an average target price of $282.12.

Danaher Trading Down 0.2 %

NYSE DHR opened at $270.03 on Tuesday. Danaher has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a 50-day moving average of $271.07 and a 200-day moving average of $258.56. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market cap of $200.01 billion, a P/E ratio of 45.77, a P/E/G ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 EPS. As a group, equities analysts predict that Danaher will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last three months. Company insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

A number of institutional investors have recently bought and sold shares of DHR. Oak Thistle LLC purchased a new stake in shares of Danaher during the 2nd quarter worth about $363,000. Caden Capital Partners LP raised its stake in shares of Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares in the last quarter. HighPoint Advisor Group LLC purchased a new stake in shares of Danaher during the 4th quarter worth about $2,614,000. Norden Group LLC purchased a new stake in shares of Danaher during the 1st quarter worth about $4,151,000. Finally, Duality Advisers LP purchased a new stake in shares of Danaher during the 1st quarter worth about $5,573,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.